Scott Innis, MS

VP, Program Lead
Foghorn Therapeutics
Cambridge, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• Paper 25 - PRELIMINARY RESULTS FROM A PHASE 1 STUDY OF FHD-609, A BROMODOMAIN-CONTAINING PROTEIN 9 DEGRADER, IN PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR SMARCB1-LOSS TUMORS

  Thursday, November 2, 2023
  4:00 PM – 5:30 PM